FELDAN THERAPEUTICS CHAIRMAN REFLECTS ON KEY ACHIEVEMENTS AT ANNUAL SHAREHOLDERS MEETING

During the Annual Shareholders Meeting of Feldan Therapeutics, held in March 2026, Chairman of the Board Dr. David J. Mazzo addressed the company’s achievements over the past year and outlined strategic priorities moving forward.

"Good afternoon, Ladies and Gentlemen,

My name is David Mazzo and I am the Chairman of the Board of Feldan Therapeutics. Along with my fellow board directors and the management team, I welcome you to our annual shareholders meeting. The last year has been a productive and even transformative year for our company, full of many accomplishments. As our CEO, Francois-Thomas, will shortly tell you, we have made great advances in our clinical and preclinical programs, increasing the interest in and value of our shuttle platform technology. Notably, François-Thomas and the team have done a tremendous job attracting new investors and sourcing new capital, including non-dilutive capital, into the company. The last several years have been a challenging time for small healthcare company financing and the fact that Feldan continues to have access to the funds needed to move our projects to their next development milestone speaks to the potential that others see in what we are doing. The management team and the board remain mindful of the trust that shareholders have endowed when they have invested. Our efforts are focused on achieving increasing shareholder value while advancing promising new drugs through development in the most cost-efficient way possible. Thank you for your continued support. From where we sit, the future looks bright indeed."

Reflecting on the chairman’s remarks, Feldan is confident in the strength of its team, its strategic direction, and the progress of its clinical and preclinical programs. Looking ahead, the Company remains focused on leveraging its unique technology to deliver innovative therapies while driving sustainable growth and long-term success.